News Author: Mary Jo Dales Publish date: January 13, 2016
News Author: Mary Jo Dales Publish date: December 23, 2015
News Author: Mary Jo Dales Publish date: December 22, 2015
News Author: Mary Jo Dales Publish date: December 18, 2015
Key clinical point: Efforts to encourage safer prescribing of opioid pain relievers should be strengthened.
Major finding: In 2014, opioids were i...
News Author: Mary Jo Dales Publish date: December 18, 2015
Key clinical point: Radotinib was associated with significantly higher complete cytogenetic responses and major molecular responses than was imati...
News Author: Mary Jo Dales Publish date: December 18, 2015
Key clinical point: Age did not affect molecular response or the incidence of adverse reactions to nilotinib among patients with CML-CP.
Major fin...
Video Author: Mary Jo Dales Publish date: December 8, 2015
News Author: Mary Jo Dales Publish date: December 8, 2015
Video Author: Mary Jo Dales Publish date: December 7, 2015
Dr. Shaji Kumar discussed the top-line Tourmaline trial results, the status of ongoing trials with ixazomib in other combination regimens, and the dec...
News Author: Mary Jo Dales Publish date: December 6, 2015
Key clinical point: IFNA17 and IFNLR1 may be important candidate genes involved in immune regulation and sustained autoimmunity in immune thromboc...
News Author: Mary Jo Dales Publish date: December 6, 2015
Key clinical point: Gene profiles can identify ALL patients under age 10 at increased risk for avascular necrosis.
Major finding: In children unde...
News Author: Mary Jo Dales Publish date: December 5, 2015
Key clinical point: Knowing which patients would not benefit from further intensification of their chemotherapy might spare them possible toxicity...
News Author: Mary Jo Dales Publish date: December 2, 2015
News Author: Mary Jo Dales Publish date: December 1, 2015
The guidelines aim to ensure that timely treatment of the cancers is not delayed in pregnant women. While rare, hematologic malignancies in pregnancy ...
News Author: Mary Jo Dales Publish date: November 5, 2015
Nucala (mepolizumab) has been approved for use with other asthma medicines as maintenance therapy for patients aged 12 years and older with a history ...
